More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Guo, Dawei ^a   Hou, Xuezhong ^b   Zhang, Hongbin ^a   Sun, Wenyu ^a   Zhu, Lei ^a   Liang, Jian ^a   Jiang, Xiaofeng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Chinese People's Liberation Army 463th hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL INVASION; CELL SURVIVAL; COMPARATIVE STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; IMMUNOLOGY; LIVER TUMOR; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; RECEPTOR, TRKB; TUMOR CELLS, CULTURED;

EID: 80053966785     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-97     Document Type: Article

References (32)

1. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J, Cancer 2000 89 500 507 10.1002/1097-0142(20000801)89: 3<500::AID-CNCR4>3.0.CO;2-O 10931448 (Pubitemid 30640096)
2. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW, Cancer Cell 2006 10 99 111 10.1016/j.ccr.2006.06.016 16904609 (Pubitemid 44202603)
3. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S, Cancer Res 1992 52 3674 3678 1319827
4. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M, J Hepatol 2003 38 200 207 12547409 (Pubitemid 36169630)
5. Trk receptor expression and inhibition in neuroblastomas. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE, Clin Cancer Res 2009 15 3244 3250 10.1158/1078-0432.CCR-08-1815 19417027
6. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H, Clin Cancer Res 2011 17 1741 1752 10.1158/1078-0432. CCR-10-1890 21350004
7. Overexpression of BDNF and TrkB in human bladder cancer specimens. Lai PC, Chiu TH, Huang YT, Oncol Rep 2010 24 1265 1270 20878119
8. Tyrosine kinase B receptor and BDNF expression in ovarian cancers-Effect on cell migration, angiogenesis and clinical outcome. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK, Cheung AN, Cancer Lett 2009 281 151 161 10.1016/j.canlet.2009.02.025 19307055
9. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Zhang Y, Fujiwara Y, Doki Y, Takiguchi S, Yasuda T, Miyata H, Yamazaki M, Ngan CY, Yamamoto H, Ma Q, Monden M, Oncology 2008 75 17 26 19092268
10. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ, Clin Cancer Res 2005 11 440 449 15701826 (Pubitemid 40116865)
11. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Yu X, Liu L, Cai B, He Y, Wan X, Cancer Sci 2008 99 543 552 10.1111/j.1349-7006.2007.00722.x 18201274 (Pubitemid 351228572)
12. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Li Z, Jaboin J, Dennis PA, Thiele CJ, Cancer Res 2005 65 2070 2075 10.1158/0008-5472.CAN-04-3606 15781614 (Pubitemid 40490110)
13. BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. Huang YT, Lai PC, Wu CC, Hsu SH, Cheng CC, Lan YF, Chiu TH, Int J Oncol 2010 36 1469 1476 20428771
14. Inhibition of brain-derived neurotrophic factor/tyrosine kinase B signaling suppresses choriocarcinoma cell growth. Kawamura N, Kawamura K, Manabe M, Tanaka T, Endocrinology 2010 151 3006 3014 10.1210/en.2009-1378 20463055
15. Brain-Derived Neurotrophic Factor Promotes Tumorigenesis via Induction of Neovascularization: Implication in Hepatocellular Carcinoma. Lam CT, Yang ZF, Lau CK, Tam KH, Fan ST, Poon RT, Clin Cancer Res 2011 17 3123 3133 10.1158/1078-0432.CCR-10-2802 21421859
16. A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. Esposito CL, D'Alessio A, de Franciscis V, Cerchia L, PLoS One 2008 3 1643 10.1371/journal.pone.0001643 18286198 (Pubitemid 351865463)
17. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL, Blood 2005 105 4429 4436 10.1182/blood-2004-08-3096 15657181 (Pubitemid 40720791)
18. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN, Oncogene 2010 29 2047 2059 10.1038/onc.2009.486 20101235
19. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS, Nature 2004 430 1034 1039 10.1038/nature02765 15329723 (Pubitemid 39128389)
20. Up-regulation of Tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations. Zhang Z, Han L, Liu Y, Liang X, Sun W, Mol Biol Rep 2009 36 1211 1216 10.1007/s11033-008-9299-z 18595003
21. Overexpression of TrkB promotes the progression of colon cancer. Yu Y, Zhang S, Wang X, Yang Z, Ou G, APMIS 2010 118 188 195 10.1111/j.1600-0463.2009. 02577.x 20132184
22. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Geiger TR, Peeper DS, Cancer Res 2007 67 6221 6229 10.1158/0008-5472.CAN-07-0121 17616679 (Pubitemid 47037503)
23. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, Evans AE, J Clin Oncol 2001 19 689 696 11157019 (Pubitemid 32119082)
24. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ, Cancer Res 2002 62 6756 6763 12438277 (Pubitemid 35364148)
25. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS, Mol Cell Biol 2009 29 3722 3737 10.1128/MCB.01164-08 19414595
26. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Li Z, Beutel G, Rhein M, Meyer J, Koenecke C, Neumann T, Yang M, Krauter J, von Neuhoff N, Heuser M, Diedrich H, Göhring G, Wilkens L, Schlegelberger B, Ganser A, Baum C, Blood 2009 113 2028 2037 10.1182/blood-2008-05-155200 19059881
27. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Perez-Pinera P, Hernandez T, García-Suárez O, de Carlos F, Germana A, Del Valle M, Astudillo A, Vega JA, Mol Cell Biochem 2007 295 19 26 10.1007/s11010-006-9267-7 16862449 (Pubitemid 46157982)
28. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, Lu Y, Cui Z, Qiu X, BMC Cancer 2010 10 43 10.1186/1471-2407-10-43 20156366
29. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM, Cancer Res 2002 62 6462 6466 12438236 (Pubitemid 35364107)
30. K252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c. Chin LS, Murray SF, Doherty PF, Singh SK, Cancer Invest 1999 17 391 395 10.3109/07357909909021430 10434949 (Pubitemid 29359885)
31. K252a inhibits the oncogenic properties of Met, the HGF receptor. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C, Oncogene 2002 21 4885 4893 10.1038/sj.onc.1205622 12118367
32. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Tapley P, Lamballe F, Barbacid M, Oncogene 1992 7 371 381 1312698